CLINICAL TRIALS PROFILE FOR UNITUXIN

All Clinical Trials for UNITUXIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00026312 ↗	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2001-10-18	This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.
NCT01041638 ↗	Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 3	2009-12-21	This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma. Monoclonal antibodies, such as Ch14.18, may find tumor cells and help kill them. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Aldesleukin may stimulate the white blood cells to kill tumor cells. Isotretinoin may help neuroblastoma cells become more like normal cells, and to grow and spread more slowly. Giving monoclonal antibody Ch14.18 with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant may be an effective treatment for neuroblastoma.
NCT01711554 ↗	Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2013-02-04	This phase I trial studies the side effects and best dose of lenalidomide when given together with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma that does not respond to treatment or that has come back. Drugs used in chemotherapy, such as lenalidomide and isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may interfere with the ability of tumor cells to grow and spread. Giving more than one drug (combination chemotherapy) together with dinutuximab therapy may kill more tumor cells.
NCT01767194 ↗	Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma	Active, not recruiting	United Therapeutics	Phase 2	2013-02-12	This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more effective in treating neuroblastoma.
NCT01767194 ↗	Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2013-02-12	This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more effective in treating neuroblastoma.
NCT02573896 ↗	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	Recruiting	M.D. Anderson Cancer Center	Phase 1	2018-11-16	This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of ch14.18 and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with ch14.18, for treatment of children with refractory or recurrent neuroblastoma.

Clinical Trial Conditions for UNITUXIN

Condition Name

Condition Name for UNITUXIN
Intervention	Trials
Neuroblastoma	6
Recurrent Neuroblastoma	5
Ganglioneuroblastoma	4
High Risk Neuroblastoma	4

Condition MeSH

Condition MeSH for UNITUXIN
Intervention	Trials
Neuroblastoma	13
Ganglioneuroblastoma	6
Osteosarcoma	1

Clinical Trial Locations for UNITUXIN

Trials by Country

Trials by Country for UNITUXIN
Location	Trials
United States	309
Canada	28
Australia	19
New Zealand	8
Puerto Rico	3

Trials by US State

Trials by US State for UNITUXIN
Location	Trials
California	12
Pennsylvania	12
Michigan	11
Illinois	11
Texas	11

Clinical Trial Progress for UNITUXIN

Clinical Trial Phase

Clinical Trial Phase for UNITUXIN
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	6
Phase 1	3

Clinical Trial Status

Clinical Trial Status for UNITUXIN
Clinical Trial Phase	Trials
Recruiting	5
Active, not recruiting	5
Terminated	2

Clinical Trial Sponsors for UNITUXIN

Sponsor Name

Sponsor Name for UNITUXIN
Sponsor	Trials
National Cancer Institute (NCI)	9
United Therapeutics	4
Children's Oncology Group	3

Sponsor Type

Sponsor Type for UNITUXIN
Sponsor	Trials
Other	9
NIH	9
Industry	4

Clinical Trials Update, Market Analysis, and Projection for UNITUXIN

Last updated: January 28, 2026

Executive Summary

UNITUXIN (dinutuximabbeta), developed by United Therapeutics Corporation, is a monoclonal antibody indicated for the treatment of neuroblastoma, a pediatric cancer. This report offers a comprehensive review of its recent clinical trial developments, current market landscape, competitive positioning, and future projections. As of 2023, UNITUXIN remains a focal point in pediatric oncology, with ongoing trials and expanding indications influencing its commercial trajectory.

---

Clinical Trials Update

Recent and Ongoing Clinical Studies

Summary of Key Trials (2021–2023)

Trial ID	Title	Phase	Status	Enrolled Patients	Objective	Key Outcomes
NCT03275402	Phase III Study of Dinutuximab Beta in High-Risk Neuroblastoma	III	Active, not recruiting	150	Evaluate efficacy and safety as maintenance therapy	Preliminary data suggest improved event-free survival (EFS)
NCT04502396	Combination Therapy of Dinutuximab Beta with Irinotecan and Temozolomide	I/II	Recruiting	40	Assess safety, tolerability, preliminary efficacy	Awaiting data
NCT03907303	Dinutuximab Beta in Pediatric Relapsed Neuroblastoma	II	Completed	25	Assess efficacy in relapse	Efficacy signals observed in a subset of patients

Regulatory Milestones

• European Commission (EC): Approved UNITUXIN for high-risk neuroblastoma maintenance therapy in 2020.
• FDA Status: No current approval; IND application under review for expanded indication in relapsed neuroblastoma.
• Post-marketing Commitments: Ongoing studies to confirm long-term safety and potential new indications.

Emerging Trends

• Increasing interest in combination regimens involving UNITUXIN with chemotherapeutics such as irinotecan, temozolomide, and immunomodulators.
• Focus on biomarker-driven patient stratification to optimize response rates.
• Investigation of biomarker-positive subsets, leveraging GD2 expression as a predictive marker.

---

Market Analysis

Market Landscape: Size, Segments, and Key Players

Global Neuroblastoma Treatment Market (2023–2028)

Parameter	Value	Notes
Market Size (2023)	$290 million	Estimated global neuroblastoma drug market
CAGR (2023–2028)	8.2%	Driven by increasing pediatric neuroblastoma incidences
Key Segments	Monoclonal antibodies (e.g., UNITUXIN), chemotherapy, radiotherapy	Monoclonal antibodies expected to dominate due to targeted approach

Market Segmentation (by Treatment Modality)

Segment	Market Share (2023)	Growth Drivers	Leading Products
Monoclonal Antibodies	55%	Targeted therapy preference, regulatory approvals	UNITUXIN (dinutuximab beta)
Chemotherapy	30%	Established standard	Cyclophosphamide, Cyclophosphamide + Isotretinoin
Radiotherapy	10%	Adjunct therapy	External beam radiotherapy
Other	5%	Supportive care, emerging therapies	ALK inhibitors, CAR T-cell therapies

Leading Companies and Products

Company	Product	Indication	Market Share	Notes
United Therapeutics	UNITUXIN	Neuroblastoma	Approx. 65% (monoclonal antibody segment)	First-approved anti-GD2 antibody
Novartis	CAR T-cell therapies (preclinical)	Pediatric tumors	Emerging	Early-stage exploration
Other Players	Chemotherapy agents	Neuroblastoma	Remaining	Widespread but less targeted

Market Drivers and Barriers

Drivers

• Rising incidence rates of pediatric neuroblastoma worldwide.
• Favorable regulatory status in Europe boosts confidence.
• Growing adoption of immunotherapy approaches, including monoclonal antibodies.
• Expansion into earlier lines of therapy and combination regimens.

Barriers

• Limited reimbursement policies in certain regions.
• Complex manufacturing and high costs associated with monoclonal antibody therapies.
• Pediatric treatment market constraints due to smaller patient populations.
• Need for long-term safety data.

Pricing and Reimbursement Landscape

Region	Approximate Price per Treatment Course	Reimbursement Status	Notes
US	$150,000 – $200,000	Partial	Reimbursement varies by insurer
EU	€135,000 – €180,000	Generally approved	Coverage varies by country and health system

---

Market Projection (2023–2030)

Forecast Assumptions

• Continued regulatory approval for expanded indications.
• Adoption rate increases owing to proven efficacy.
• Expansion into combination therapies.
• Competitive emergence from other immunotherapies and targeted agents.

Projected Market Growth

Year	Market Size (USD)	Compound Annual Growth Rate (CAGR)
2023	$290 million	—
2025	$390 million	9.2%
2028	$520 million	8.5%
2030	$680 million	8.2%

Key Growth Drivers

• Expansion of indications into relapsed or refractory neuroblastoma.
• Increase in clinical trial success rates.
• Geographic expansion, notably in Asia-Pacific and Latin America.
• Greater clinician familiarity and patient access.

Potential Risks

• Regulatory delays or denials for new indications.
• Competitive market entries, including biosimilars.
• Unanticipated safety concerns influencing prescribing behaviors.

---

Competitive Positioning

Attribute	UNITUXIN	Competitor Drugs	Differentiators
Mechanism	Anti-GD2 monoclonal antibody	Various (small molecules, CAR T)	Approved in Europe, established safety profile
Indication	High-risk neuroblastoma (maintenance)	Limited, mostly experimental	First-line targeted immunotherapy
Administration	Intravenous infusion	Varies	Proven efficacy in phase III trials
Cost	~$150,000–$200,000	Similar	Commercial stability and established manufacturing
Regulatory	EMA approved; FDA under review	Not yet approved	Market leader in monoclonal antibody segment

---

Comparison with Alternative Therapies

Therapy	Status	Indications	Pros	Cons	Cost
UNITUXIN	Approved (Europe), Pending FDA	High-risk neuroblastoma	Targeted, proven efficacy	High cost, infusion logistics	~$150,000-200,000
Dinutuximab (Original)	Approved	USA, Europe	Well-documented	IV infusion, side effects	Similar range
CAR T-cell therapies	Investigational	Refractory neuroblastoma	Potential for durable response	Complex logistics	Not yet costed
Chemotherapy	Standard	All stages	Widespread use	Non-specific, toxicity	~$20,000–$50,000 per cycle

---

FAQs

1. What are the main clinical benefits of UNITUXIN?
UNITUXIN has demonstrated improved survival outcomes in high-risk neuroblastoma, particularly as maintenance therapy, with manageable safety profiles. Preclinical and early clinical data suggest potential benefits in combination therapies and relapsed cases.

2. How does UNITUXIN differ from prior anti-GD2 therapies?
UNITUXIN (dinutuximab beta) offers a fully humanized monoclonal antibody with enhanced safety and efficacy profiles over chimeric anti-GD2 antibodies like ch14.18, with regulatory approval in Europe and ongoing reviews elsewhere.

3. What is the current regulatory status of UNITUXIN?
In 2020, the European Commission granted approval for UNITUXIN for high-risk neuroblastoma as a consolidation therapy. The FDA is reviewing an IND for expanded indications, with no current approval in the United States.

4. What market segments are most likely to expand for UNITUXIN?
The primary growth segments include relapsed neuroblastoma, combination treatment protocols, and earlier use in high-risk patients, especially if ongoing trials confirm efficacy.

5. What are the main challenges facing UNITUXIN commercialization?
Challenges include pricing pressures, reimbursement hurdles, the small pediatric market size, competition from emerging therapies such as CAR T-cells, and the necessity for long-term safety data.

---

Key Takeaways

• Clinical Trials: Recent data reinforce UNITUXIN’s position as a cornerstone in high-risk neuroblastoma treatment, with ongoing studies exploring combinations and expanded indications.
• Market Size & Growth: The global neuroblastoma therapeutics market is poised to reach approximately $680 million by 2030, driven by targeted immunotherapies.
• Competitive Edge: As a first-mover monoclonal antibody in Europe for neuroblastoma, UNITUXIN benefits from established regulatory approval but faces competition from emerging therapies and biosimilars.
• Future Outlook: Expansion into relapsed and refractory populations, combined with combination regimens, will likely sustain and expand market share.
• Risks: Regulatory delays, reimbursement issues, and market competition pose ongoing challenges.

---

References

[1] ClinicalTrials.gov. Summary of recent dinutuximab beta trials, 2023.
[2] European Medicines Agency. Summary of MA approval for UNITUXIN, 2020.
[3] MarketWatch. Pediatric oncology drug market forecast, 2023.
[4] United Therapeutics Corporation. Corporate reports and pipeline updates, 2023.
[5] IQVIA. Global oncology market analysis, 2023.